**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Giuseppe Damiano Sanna
1. Amyloidosis Research and Treatment Center, Department of Molecular Medicine, Foundation IRCCS Policlinico San Matteo, Pavia (Italy)
2. Clinical and Interventional Cardiology, Sassari University Hospital, Sassari (Italy)

**Main Body of the Abstract**
Data regarding evolution over time of echocardiographic features in TTRwt amyloidosis is scarce.                                                                The baseline and follow-up echocardiograms of patients treated with tafamidis from our prospectively maintained database (NCT05444920) were reviewed. Changes between baseline and second follow-up evaluations (scheduled at 12 months) were tested for significance.                                                                                                                                                                                                                         We included 151 patients (Table). There were no significant differences between baseline and follow-up in terms of left ventricular (LV) geometry (median interventricular septum thickness 18[15-20]vs18[16-20]mm, p=0.377; end-diastolic diameter 45[40-49]vs43[40-49]mm, p=0.890) and systolic function (ejection fraction 50±11% vs 49±11%, p=0.054; global longitudinal strain -12.3±-3.6% vs -12.4±-5.1%, p=0.788). Similarly, we did not find significant differences in terms of LV filling pressures (increased in 91vs 85% of patients, p=0.219; E/e’ ratio 16.8[11.2-20]vs14.5[12.6-19.2], p=0.071) and left atrial (LA) size (mean LA volume indexed for body surface area 46±16vs48±12 ml/m2, p=0.410). Moreover, right ventricular longitudinal function assessed through the tricuspid annular plane systolic excursion (TAPSE) was similar between baseline and follow-up (17[14-20]vs17[14-20]mm). Finally, there were no significant changes of estimated pulmonary artery systolic pressure - ePASP (40[33-45]vs35[30-44]mmHg) over the follow-up period. Tafamidis may prevent worsening of the main echocardiographic indices used to monitor cardiac remodeling and dysfunction induced by amyloid infiltration. Larger case-control studies with longer follow-up will clarify the potential impact of tafamidis in improving these echocardiographic indices, and their utility (with best cut-off values) to predict and monitor treatment response.



**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Giuseppe Damiano Sanna
_1._ _Amyloidosis Research and Treatment Center, Department of Molecular Medicine, Foundation IRCCS Policlinico San Matteo, Pavia (Italy)_
_2. Clinical and Interventional Cardiology, Sassari University Hospital, Sassari (Italy)_

**Main Body of the Abstract**
Data regarding evolution over time of echocardiographic features in TTRwt amyloidosis is scarce.                                                                The baseline and follow-up echocardiograms of patients treated with tafamidis from our prospectively maintained database (NCT05444920) were reviewed. Changes between baseline and second follow-up evaluations (scheduled at 12 months) were tested for significance.**                                                                                                                                                                                                                         **We included 151 patients (Table). There were no significant differences between baseline and follow-up in terms of left ventricular (LV) geometry (median interventricular septum thickness 18[15-20]_vs_18[16-20]mm, _p_=0.377; end-diastolic diameter 45[40-49]_vs_43[40-49]mm, _p_=0.890) and systolic function (ejection fraction 50±11% _vs_ 49±11%, _p_=0.054; global longitudinal strain -12.3±-3.6% _vs_ -12.4±-5.1%, _p_=0.788). Similarly, we did not find significant differences in terms of LV filling pressures (increased in 91vs 85% of patients, _p_=0.219; E/e’ ratio 16.8[11.2-20]_vs_14.5[12.6-19.2], _p_=0.071) and left atrial (LA) size (mean LA volume indexed for body surface area 46±16_vs_48±12 ml/m2, _p_=0.410). Moreover, right ventricular longitudinal function assessed through the tricuspid annular plane systolic excursion (TAPSE) was similar between baseline and follow-up (17[14-20]_vs_17[14-20]mm). Finally, there were no significant changes of estimated pulmonary artery systolic pressure - ePASP (40[33-45]_vs_35[30-44]mmHg) over the follow-up period. Tafamidis may prevent worsening of the main echocardiographic indices used to monitor cardiac remodeling and dysfunction induced by amyloid infiltration. Larger case-control studies with longer follow-up will clarify the potential impact of tafamidis in improving these echocardiographic indices, and their utility (with best cut-off values) to predict and monitor treatment response.



Evolution over time of echocardiographic features in patients with wild-type transthyretin cardiac amyloidosis PB1324 (#505)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.